ReviewCurrent oncology reports2012
FGF receptor inhibitors: role in cancer therapy.
Review in Current oncology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.Targeted oncology · 2016Pooled it
- Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Small molecule inhibitors of the VEGF and tyrosine kinase for the treatment of cervical cancer.Medical oncology (Northwood, London, England) · 2024Review
- Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis.Oncology letters · 2023Article
- Review
- Review
- Induction of entosis in prostate cancer cells by nintedanib and its therapeutic implications.Oncology letters · 2019Article
- Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.Acta biomaterialia · 2019Article
- RETRACTED: Fluorinated Analog NMR s of Organosulfur Compounds from Garlic (Allium sativum): Synthesis, Chemistry and Anti-Angiogenesis and Antithrombotic Studies.Molecules (Basel, Switzerland) · 2017Article
- Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study.Oncotarget · 2017Article
- Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).Journal of biomedical science · 2017Article
- Recombinant expression inPeerJ · 2017Article
- Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.Cancer letters · 2016Review
- Fibroblast growth factors, old kids on the new block.Seminars in cell & developmental biology · 2016Review
- Toward precision medicine of breast cancer.Theoretical biology & medical modelling · 2016Review
- Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.World journal of gastroenterology · 2016Review
- Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma.Cancer medicine · 2016Article
- Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.Molecular cancer · 2015Article
- Article
- Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication.Advances in wound care · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The fibroblast growth factor (FGF) signaling pathway is implicated as a key driver of tumor progression and growth via the dysregulation of cell proliferation, differentiation, survival, and angiogenesis in multiple tumor types. In addition, it may serve as a mechanism of resistance to antivascular endothelial growth factor targeted therapy. As such this pathway has emerged as a relevant therapeutic target, and several agents that can inhibit or modulate its signaling are in various stages of development. This review will summarize the current clinical status of agents targeting FGF receptors. In addition, strategies to accelerate the clinical development of these targeted agents will be presented.
Indexed as
Identifiers
22311684What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.